Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0189

Scientific exchange · Dr. Andrea Fischer

25 Apr 2026 · Virtual · Dr. Andrea Fischer, Osaka University Hospital · MSL Luis Ortega · Lumeva

ReviewedVeeva CRMENG-0189—

Capture insight from this engagement

Location: Osaka University Hospital
Therapeutic area: Neurology
Country: Japan
Stakeholder tier: Tier 2
Strategic objective: Not linked
Initiative: Not linked
MSL: LOLuis OrtegaMSL, Neurology (Iberia)
Product: Lumeva (lumevarin)

Topics discussed

Real-world persistence

Scientific content used

Chronic migraine scientific platform
LMV persistence data summary

Questions raised

What is the persistence rate at 18 months in real-world cohorts?

Notes

Scientific exchange with general neurologist at Osaka University Hospital. Discussed real-world persistence.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Send publication reprint

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 2
Strategic relevance: 3
Depth of exchange: 4
Actionability: 1

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0189

Audit history (0)

All create, update and approval events for this record

No audit events in sample data